Want to see AIMD full AI Analyst Report?
AIMD Stock Chart & Stats
$1.40
-$0.05(-3.57%)
At close: 4:00 PM EDT
$1.40
-$0.05(-3.57%)
Day’s Range― - ―
52-Week Range$1.26 - $4.44
Previous CloseN/A
Volume31.95K
Average Volume (3M)78.00K
Market Cap
$10.49M
Enterprise Value$26.66
Total Cash (Recent Filing)$1.42M
Total Debt (Recent Filing)$13.81M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding7,384,073
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Therapeutics And Diagnostics FocusA dual focus on exosome-based therapeutics and diagnostic sensor platforms provides multiple commercialization pathways and reduces dependence on a single product. Structurally, this diversification can smooth revenue timing and create cross-selling opportunities across pharma and diagnostics markets over 2–6 months and beyond.
Proprietary AI-enabled Sensing And Exosome TechOwning AI-enabled sensing IP and exosome-based approaches can create a defensible technical moat if validated. Durable advantages include data-driven improvements, potential recurring diagnostic revenues, and licensing opportunities that support margin expansion and strategic partnerships over the medium term.
Near-term Liquidity Secured Via Bank FacilityThe unsecured three-month credit line provides immediate runway and operational flexibility without collateral or equity dilution. While short dated, it reduces near-term financing pressure, preserves optionality to pursue trials or commercialization steps, and buys time to pursue longer-term funding.
Bears Say
Declining Revenue With Large Net LossesSustained revenue decline and persistent large net losses indicate the core business is not scaling to cover costs. Over months this undermines the path to breakeven, increases reliance on external capital, and constrains resources for R&D or commercial launches, impairing strategic execution.
Persistent Negative Operating And Free Cash FlowConsistent cash burn means the company cannot self-fund operations or development. This structural cash shortfall necessitates frequent financing, raising dilution or debt risk, and limits the ability to invest in trials, regulatory activities, or commercial scaling over the medium term.
Rising Leverage And Diminished Equity CushionA sharply reduced equity base and higher debt ratio materially increase balance-sheet risk. Elevated leverage restricts financial flexibility, raises default and covenant vulnerability, and heightens interest burdens—making sustained operations and investment more contingent on successful financing events.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.44 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $10.49M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is Nov 11, 2026 which is in 85 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on Aug 03, 2026. The company reported -$0.624 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 7,384,073 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.624 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.759%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―
Ownership Overview
48.13% Insiders
0.43% Mutual Funds
0.37% Other Institutional Investors
50.85% Public Companies and
Individual Investors